Fetzima Capsule, Extended Release
Product Images NDC 0456-2240

10 FDA label images from Allergan, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Fetzima (NDC 0456-2240). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Allergan, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

The Chemical Structure Of Fetzima Is Levomilnacipran, Which Is A Selective Serotonin And Norepinephrine Reuptake Inhibitor (snri). The Chemical Name Of Levomilnacipran Is (1s,2r)-2-(aminomethyl)-n,n-diethyl-1-phenylcyclopropanecarboxamide Hydrochloride; Its Empirical Formula Is C15h23cln2o And Its Molecular Weight Is 282.8 G/mol. Levomilnacipran (initial Us Approval: 2013) Is The 1s,2r-enantiomer Of Milnacipran. (Fetzima 01)

The Chemical Structure Of Fetzima Is Levomilnacipran, Which Is A Selective Serotonin And Norepinephrine Reuptake Inhibitor (snri). The Chemical Name Of Levomilnacipran Is (1s,2r)-2-(aminomethyl)-n,n-diethyl-1-phenylcyclopropanecarboxamide Hydrochloride; Its Empirical Formula Is C15h23cln2o And Its Molecular Weight Is 282.8 G/mol. Levomilnacipran (initial Us Approval: 2013) Is The 1s,2r-enantiomer Of Milnacipran. (Fetzima 01)
Chemical structure diagram of levomilnacipran hydrochloride, the active ingredient in Fetzima oral medication. The structure shows molecular bonds and key functional groups typical to this compound.*
FDA Label Image

Figure_en_071213 (Fetzima 02)

Figure_en_071213 (Fetzima 02)
A chart depicting fold change and 90% confidence intervals for levomilnacipran hydrochloride (LVM) drug interactions involving CYP3A4 inhibitors, inducers, and substrates. The chart shows Cmax and AUC changes relative to reference when LVM is combined with ketoconazole, carbamazepine, and alprazolam, illustrating the impact on pharmacokinetics.*
FDA Label Image

Figure_in_071213 (Fetzima 03)

Figure_in_071213 (Fetzima 03)
A fold change and 90% confidence interval forest plot depicting pharmacokinetic parameters (Cmax and AUC) for different population subgroups: age above 65 years, gender (females), and various degrees of renal and hepatic impairment (mild, moderate, severe). The x-axis indicates change relative to reference values, illustrating variations in drug exposure across these populations.*
FDA Label Image

Figure 3. Kaplan-meier Estimated Proportion Of Patients With Relapse For Adults With Mdd (study 4) (Fetzima 04)

Figure 3. Kaplan-meier Estimated Proportion Of Patients With Relapse For Adults With Mdd (study 4) (Fetzima 04)
A Kaplan-Meier survival curve chart showing the proportion of patients with relapse over time (days) comparing Fetzima and placebo groups. The graph plots relapse rates from randomization to approximately 200 days, with Fetzima showing a lower relapse proportion than placebo. Patient counts at risk are listed below the x-axis across several time points.*
FDA Label Image

Rx Only Ndc 0456-2220-30fetzima®levomilnacipranextended-release Capsules20 mg Per Capsuledispense The Accompanyingmedication Guide To Each Patient.30 Capsules (Fetzima 05)

Rx Only  Ndc 0456-2220-30fetzima®levomilnacipranextended-release Capsules20 mg Per Capsuledispense The Accompanyingmedication Guide To Each Patient.30 Capsules (Fetzima 05)
The packaging label for Fetzima levomilnacipran extended-release capsules, 20 mg per capsule. The label shows a carton panel with a 30-capsule count and includes usage instructions, storage conditions, and manufacturer details. It is distributed by Allergan USA, Inc., Madison, NJ.*
FDA Label Image

Rx Only Ndc 0456-2240-30fetzima®levomilnacipranextended-release Capsules40 mg Per Capsuledispense The Accompanyingmedication Guide To Each Patient.30 Capsules (Fetzima 06)

Rx Only  Ndc 0456-2240-30fetzima®levomilnacipranextended-release Capsules40 mg Per Capsuledispense The Accompanyingmedication Guide To Each Patient.30 Capsules (Fetzima 06)
Label for Fetzima levomilnacipran extended-release capsules, 40 mg per capsule. The label states it is a prescription capsule product containing 30 capsules, distributed by Allergan USA, Inc. It includes storage instructions, dosage form, and notes that it is licensed from Pierre Fabre Medicament and made in France.*
FDA Label Image

Rx Only Ndc 0456-2280-30fetzima®levomilnacipranextended-release Capsules80 mg Per Capsuledispense The Accompanyingmedication Guide To Each Patient.30 Capsules (Fetzima 07)

Rx Only  Ndc 0456-2280-30fetzima®levomilnacipranextended-release Capsules80 mg Per Capsuledispense The Accompanyingmedication Guide To Each Patient.30 Capsules (Fetzima 07)
Fetzima 80 mg extended-release capsules packaging label shows the proprietary name Fetzima and the generic name levomilnacipran. The label states it is for oral use, prescription only, and contains 30 capsules. It includes storage instructions, dosage form, and distributor Allergan USA, Inc. information.*
FDA Label Image

Rx Only Ndc 0456-2212-30fetzima®levomilnacipranextended-release Capsules120 mg Per Capsuledispense The Accompanyingmedication Guide To Each Patient.30 Capsules (Fetzima 08)

Rx Only  Ndc 0456-2212-30fetzima®levomilnacipranextended-release Capsules120 mg Per Capsuledispense The Accompanyingmedication Guide To Each Patient.30 Capsules (Fetzima 08)
Fetzima 120 mg extended-release capsules label displaying the proprietary and generic name levomilnacipran hydrochloride, dosage strength, and dosage form. The label shows it is a prescription drug distributed by Allergan, Inc. It contains 30 capsules and includes storage instructions and safety warnings on the right side.*
FDA Label Image

Rx Only Ndc 0456-2202-28fetzima®levomilnacipranextended-release Capsulestitration Packtwo 20 mg Capsulestake One 20 mg Capsule Once Dailyon Day 1 And Day 2. Twenty-six 40 mg Capsulestake One 40 mg Capsule Once Dailyon Day 3 Through Day 28.patients: Lift Up Flap To Find Instructions For Sliding Out The Tray.dispense The Accompanying Medication Guide To Each Patient. (Fetzima 09)

Rx Only  Ndc 0456-2202-28fetzima®levomilnacipranextended-release Capsulestitration Packtwo 20 mg Capsulestake One 20 mg Capsule Once Dailyon Day 1 And Day 2. Twenty-six 40 mg Capsulestake One 40 mg Capsule Once Dailyon Day 3 Through Day 28.patients: Lift Up Flap To Find Instructions For Sliding Out The Tray.dispense The Accompanying Medication Guide To Each Patient. (Fetzima 09)
Label for Fetzima levomilnacipran extended-release capsules Titration Pack by Allergan, Inc. The kit contains two 20 mg capsules and twenty-six 40 mg capsules. Directions include taking two 20 mg capsules once daily on Days 1 and 2, then one 40 mg capsule once daily from Day 3 through Day 28. The label features instructions for use and medication guide information.*
FDA Label Image

Rx Only Ndc 0456-2200-07professional Sample-not For Salefetzima®levomilnacipranextended-release Capsulestwo 20 mg Capsulestake One 20 mg Capsule Once Dailyon Day 1 And Day 2. Five 40 mg Capsulestake One 40 mg Capsule Once Dailyon Day 3 Through Day 7.dispense The Accompanying Medication Guide To Each Patient. (Fetzima 0a)

Rx Only  Ndc 0456-2200-07professional Sample-not For Salefetzima®levomilnacipranextended-release Capsulestwo 20 mg Capsulestake One 20 mg Capsule Once Dailyon Day 1 And Day 2. Five 40 mg Capsulestake One 40 mg Capsule Once Dailyon Day 3 Through Day 7.dispense The Accompanying Medication Guide To Each Patient. (Fetzima 0a)
Packaging label for Fetzima, a kit of extended-release capsules containing levomilnacipran. The kit includes two 20 mg capsules and five 40 mg capsules. The label advises dosing instructions, storage conditions, and notes that it is a professional sample not for sale. The product is manufactured by Allergan, Inc., a subsidiary of AbbVie.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.